Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

nts who discontinued study therapy in ETV-027, and subsequently restarted treatment in rollover study ETV-901, with a greater than 60 day gap between end of treatment in study ETV-027 and start of treatment in study ETV-901.

    -- ETV-027 compared 0.5 mg of BARACLUDE vs. 100 mg of lamivudine in
nucleoside-naive chronic HBeAg-negative chronic hepatitis B patients.
-- Rollover study ETV-901 was established as an open-label, follow-up
protocol for patients in phase II and III studies of BARACLUDE.
-- Due to ongoing blinding of study ETV-027, most patients retreated in
ETV-901 initially received a combination of 1 mg of BARACLUDE plus 100
mg of lamivudine, and were subsequently switched to 1 mg of BARACLUDE
monotherapy.

The analysis cohort was defined regardless of treatment response at the end of dosing in study ETV-027, and independent of virologic or ALT measurements at the start of dosing in study ETV-901. During off-treatment follow-up, the majority of patients had recurrent levels of hepatitis B virus in the blood (viremia) and increases in ALT.

    Data Results
At the end of dosing for study ETV-027:
-- 94 percent (n=93/99) of the re-treatment cohort had undetectable viral
load
-- 78 percent (n=77/99) had ALT normalization
At entry into ETV-901:
-- Four percent (n=4/99) of patients had undetectable viral load
-- Eight percent (n=8/97) of patients had ALT normalization
Following re-treatment in study ETV-901:
-- 93 percent (n=82/88) of patients had undetectable viral load (HBV DNA
<300 copies/mL) by week 48 of re-treatment with BARACLUDE
-- 83 percent (n=79/95) of patients had ALT normalization (ALT less than
or equal to 1 times the upper limit of normal) by week 48 of re-
treatment BARACLUDE
Adverse events in study ETV-027/901 re-treatment cohort:
-- 67 percent (n=66/99) of patients experienced an adverse event. The most
common adverse events occurring in greater than ten percent of patients
were abdominal pain, fa
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:9/2/2014)... , Spanien, September 2, 2014 ... Das auf dem ESC-Kongress 2014 präsentierte ... Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten Patienten ... Die Daten der ... Patienten, einer innovativen und unabhängigen Forschungsinitiative ...
(Date:9/2/2014)... September 2, 2014 , ... 2014 provide insight into treatment and outcomes of ... practice --   Data from nearly ... in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent ... strategies for atrial fibrillation (AF) patients remain sub-optimal ...
(Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, the ... its investment in development and manufacturing capabilities with the ... Karl Mueller , Particle Sciences, Associate Director Clinical Production, ... adding clean room square footage, equipment and staff across ... The company now has over 6000ft 2 of ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
... , ... The Gamida Cell-Teva Joint Venture,(JV) announced today that the ... registration, Phase,III clinical trial of StemEx (called ExCell) and has recommended ... data analysis is,anticipated to take place during Q2 2010. StemEx is ...
... , Feb. 9 CareFusion Corp. (NYSE: ... from continuing operations for the three and six months ended ... during our second quarter and performed ahead of our expectations," said ... spending made modest improvements during the quarter and we continued to ...
Cached Medicine Technology:Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 2Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 3CareFusion Reports Second Quarter Results 2CareFusion Reports Second Quarter Results 3CareFusion Reports Second Quarter Results 4CareFusion Reports Second Quarter Results 5CareFusion Reports Second Quarter Results 6CareFusion Reports Second Quarter Results 7CareFusion Reports Second Quarter Results 8CareFusion Reports Second Quarter Results 9CareFusion Reports Second Quarter Results 10CareFusion Reports Second Quarter Results 11CareFusion Reports Second Quarter Results 12CareFusion Reports Second Quarter Results 13CareFusion Reports Second Quarter Results 14CareFusion Reports Second Quarter Results 15CareFusion Reports Second Quarter Results 16CareFusion Reports Second Quarter Results 17CareFusion Reports Second Quarter Results 18
(Date:9/2/2014)... State University biochemists have discovered a family of proteins ... aureus , a pathogenic bacterium that can cause more ... Geisbrecht, professor of biochemistry and molecular biophysics, and Kasra ... , which is the cause of increasing common staph ... Proceedings of the National Academy of Sciences , or ...
(Date:9/2/2014)... have made it clear that a mother,s eating habits ... a profound impact on her offspring and their propensity ... now, the mechanisms behind this phenomenon were unclear. According ... of The FASEB Journal F , scientists ... a mother,s diet and an offspring,s risk of future ...
(Date:9/2/2014)... Many people believe that marijuana is not addictive, but ... people are able to obtain and consume cannabis legally ... are less likely to perceive it as addictive or ... General Hospital,s Center for Addiction Medicine, said in a ... use can have significant consequences, and we know that ...
(Date:9/2/2014)... Malvern, PA (PRWEB) September 02, 2014 ... healthcare communications and education, is proud to announce the ... and clinical resource center designed for healthcare professionals who ... website offers practitioners comprehensive access to:, , ... , Dedicated topic centers for diabetes, oncology, ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Healthcare professionals ... and most complete oncology guidelines available at the point ... and the National Comprehensive Cancer Network® ... other evidence and guidelines in the content available from ... , NCCN, a not-for-profit alliance of 25 of the ...
Breaking Medicine News(10 mins):Health News:Biochemists find new treatment options for staph infections, inflammatory diseases 2Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:'Pot Addiction' May Be Real, Study Suggests 2Health News:HMP Communications Holdings, LLC, Acquires Nutrition411.com 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4
... growth of cancer cells in lab study , THURSDAY, Nov. ... form of leukemia holds promise as a possible treatment for ... (Sprycel) is used to treat chronic myeloid leukemia. Researchers at ... drug limited the growth and invasive powers of ovarian cancer ...
... ... and his company, Nationwide Relocation Services, are enormous supporters of breast cancer ... lethal disease are growing by number, as both men and women are ... its power to assist in costumers, moves when coping with such difficult ...
... ... PDF conversion product line. PDF2Office® for iWork a new product to convert PDF to ... ... Recosoft Corporation the developer of the PDF2Office® family of products, PDF2ID® tool for InDesign®, ...
... ... are under even more pressure to perform during the swine flu ... large and small over the coming months. While some large businesses ... for their employees, many medium and smaller businesses are not protected. ...
... FREEHOLD, N.J., Nov. 11 Speedus Corp. (Nasdaq: SPDE ... Graham was appointed to the Company,s Board of Directors. , ... which he founded in 1988, and has been a General ... Crosshill Debt II, L.P. since 2004. Prior to these roles ...
... Forward thinking Mayor A.C. Wharton, sees Benefit in New ... Memphis Mayor, A.C. Wharton stands up for the outstanding ... hosted by University of Tennessee Health & Science Center on ... Madison in Room 305. The National Bipolar Foundation has been ...
Cached Medicine News:Health News:Leukemia Drug May Help Some Ovarian Cancer Patients 2Health News:Nationwide Relocation Services Support Breast Cancer Awareness 2Health News:Nationwide Relocation Services Support Breast Cancer Awareness 3Health News:PDF2Office for iWork -- New Utility to Convert PDF Files Directly to Native Keynote & Pages '08/'09 Formats Ships 2Health News:PDF2Office for iWork -- New Utility to Convert PDF Files Directly to Native Keynote & Pages '08/'09 Formats Ships 3Health News:How to Survive Recession and Swine Flu Outbreak in Your Employees 2Health News:Speedus Corp. Names Stephen X. Graham to Board of Directors 2Health News:Memphis Mayor Endorses National Bipolar Foundation 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: